AffaMed Therapeutics

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Glucocorticoid receptorSmall molecule
Allergic ConjunctivitisOcular Inflammation
Ocular Inflammation and Pain
Phase 3
Nasal chemosensory receptorsSmall molecule
Social Anxiety Disorder

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 August 2026Topline resultfasedienolExploratory Phase 2 repeat-dose study of fasedienol: primary endpoint not statistically significant
VistaGen Therapeutics · Source ↗
30 June 2026Topline resultfasedienolPhase 3 PALISADE-4 of fasedienol did not meet its primary endpoint
VistaGen Therapeutics · Source ↗
June 2026Topline resultfasedienolPALISADE-4 randomized portion missed primary endpoint

Financial reports

No financial reports recorded.